scholarly article | Q13442814 |
P50 | author | Andrew W. Roberts | Q43445505 |
Constantine S. Tam | Q55445006 | ||
David C Huang | Q56987660 | ||
Joshua Fein | Q57117994 | ||
Ian J Majewski | Q62263878 | ||
Mary Ann Anderson | Q82872506 | ||
Anthony Letai | Q88032748 | ||
P2093 | author name string | John F Seymour | |
Jennifer R Brown | |||
Matthew S Davids | |||
Su Young Kim | |||
Jing Deng | |||
David Segal | |||
Lijian Yu | |||
David Westerman | |||
Sari L Heitner Enschede | |||
Eric G Si | |||
P2860 | cites work | The Hallmarks of Cancer | Q221226 |
Hallmarks of Cancer: The Next Generation | Q22252312 | ||
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members | Q24337108 | ||
miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 | ||
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 | ||
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
TP53 mutation and survival in chronic lymphocytic leukemia | Q27851577 | ||
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa | Q28204059 | ||
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity | Q28268312 | ||
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia | Q28394721 | ||
Tumor spectrum analysis in p53-mutant mice | Q29617436 | ||
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
Clearance of apoptotic cells: implications in health and disease | Q30433781 | ||
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 | ||
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. | Q33412553 | ||
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy | Q35761070 | ||
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia | Q36352532 | ||
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
Targeting the B-cell lymphoma/leukemia 2 family in cancer | Q38014808 | ||
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. | Q38172752 | ||
Targeting BCL2 for the treatment of lymphoid malignancies | Q38232485 | ||
Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. | Q38791801 | ||
An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo | Q38904501 | ||
A unified model of mammalian BCL-2 protein family interactions at the mitochondria. | Q39292731 | ||
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome | Q41223060 | ||
Genetic analysis of chemoresistance in primary murine lymphomas. | Q43422059 | ||
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. | Q45916401 | ||
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. | Q50858312 | ||
DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 | Q57338694 | ||
P433 | issue | 25 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
apoptotic process | Q14599311 | ||
P304 | page(s) | 3215-3224 | |
P577 | publication date | 2016-04-11 | |
P1433 | published in | Blood | Q885070 |
P1476 | title | The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism | |
P478 | volume | 127 |
Q64120024 | A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy |
Q60480019 | ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells |
Q39227773 | Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia |
Q50074012 | Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies |
Q90425403 | BCL-2 inhibition in AML: an unexpected bonus? |
Q91992641 | BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models |
Q37588301 | Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport |
Q93376413 | Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas |
Q39006397 | Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia |
Q53699332 | Delineation of the androgen-regulated signaling pathways in prostate cancer facilitates the development of novel therapeutic approaches. |
Q37702281 | Development of venetoclax for therapy of lymphoid malignancies. |
Q39027800 | Diffuse large B-cell lymphoma: R-CHOP failure-what to do? |
Q56811078 | Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening |
Q100750110 | Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome |
Q93223071 | Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma |
Q51737093 | Emerging molecular mechanisms in chemotherapy: Ca2+ signaling at the mitochondria-associated endoplasmic reticulum membranes. |
Q47670541 | Emerging molecular predictive and prognostic factors in acute myeloid leukemia |
Q91994349 | Emerging treatment options for patients with p53-pathway-deficient CLL |
Q61454350 | Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells |
Q37209768 | High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells |
Q37587294 | How to unleash mitochondrial apoptotic blockades to kill cancers? |
Q38904537 | Integrating functional genomics to accelerate mechanistic personalized medicine |
Q38943877 | Magic pills: new oral drugs to treat chronic lymphocytic leukemia. |
Q49692075 | Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia |
Q52582842 | Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. |
Q28069552 | Mitochondrial apoptosis and BH3 mimetics |
Q38636162 | Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. |
Q58602178 | NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death |
Q47661789 | Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration |
Q51160342 | Pathways and mechanisms of venetoclax resistance. |
Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
Q33438494 | Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
Q91474390 | Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma |
Q38997367 | Predictive and prognostic biomarkers in the era of new targeted therapies for chronic lymphocytic leukemia |
Q40041785 | Regulation of Apoptosis during Flavivirus Infection |
Q90399550 | Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies |
Q55379234 | Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile. |
Q50906605 | TP53 in adult acute lymphoblastic leukemia. |
Q38982682 | Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). |
Q38738661 | Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future |
Q39456786 | Targeting BCL-2-like Proteins to Kill Cancer Cells |
Q38996888 | Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies |
Q90747788 | Targeting Bcl-2 for the treatment of multiple myeloma |
Q90047057 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer |
Q55017371 | Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia. |
Q92951967 | Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide |
Q47166330 | The BCL-2 arbiters of apoptosis and their growing role as cancer targets |
Q38766548 | The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia |
Q89493561 | The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma |
Q42371592 | The genetically engineered drug rhCNB induces apoptosis via a mitochondrial route in tumor cells |
Q49989104 | The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment |
Q51014811 | The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. |
Q38798849 | To Prime, or Not to Prime: That Is the Question |
Q64904346 | Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. |
Q59333353 | VDAC2 enables BAX to mediate apoptosis and limit tumor development |
Q90071201 | Venetoclax for the Treatment of Chronic Lymphocytic Leukemia |
Q47875923 | Venetoclax for the treatment of chronic lymphocytic leukemia. |
Q38685358 | Venetoclax for the treatment of patients with chronic lymphocytic leukemia |
Q64074946 | Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement |
Q33433407 | Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. |
Q90203333 | Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia |
Q47159040 | Why do BCL-2 inhibitors work and where should we use them in the clinic? |
Q37678946 | miR-125b-5p enhances chemotherapy sensitivity to cisplatin by down-regulating Bcl2 in gallbladder cancer |
Search more.